Illumina scoops up Oxford Nanopore's core technology for a steal

Illumina (Nasdaq: ILMN) recently signed an exclusive worldwide agreement with Oxford Nanopore Technologies (see the December 8, 2008 LRBJ) providing Illumina with the rights to Oxford Nanopore’s BASE (Bayley Sequencing) technology for the marketing, sales, distribution, and servicing of BASE in both...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email Thank you!

Related Research

23andMe expands portfolio of approved cancer screenings with latest FDA approval

News Commentary | January 13, 2022

The U.S. FDA has given 23andMe approval to expand its genetic health risk report by screening for a G84E mutation in the HOXB13 gene. This mutation has been linked to an increase in prostate cancer. A recent study showed that males with a G84E gene mutation were 66% more likely to have prostate ... To read more, click here.


Company Profile | May 13, 2022

​​​​​Develops a rapid pathogen detection platform,TrueRapid; the system works by selectively capturing only live pathogenic bacteria cells by binding to aptamers Claims the system is capable of delivering quantitative analysis for the presence of food pathogens in 20 minutes and reducing the ... Not part of subscription


Company Profile | April 06, 2022

Developer of DNAFoil, B3, and BEAMitup — rapid DNA tests for food authentication and compliance; intends to sell compliance‑as‑a‑service via BEAMitup and ISO17025 certificates Company utilizes library of 200,000 unique DNA fingerprints to create onsite DNA tests with results in 30 minutes ... Not part of subscription